Skip to Content

Join the 'Venclexta' group to help and get support from people like you.

Venclexta News

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less able to afford cancer drugs than Americans, he said, even though U.S. monthly drug prices are about three to six times higher in the United States. That doesn't mean America came out on top in overall drug affordability, however. Developed nations such as Australia, England and Israel had the "best deal" in the world on cancer drugs, thanks to government programs that regulate drug pricing, the study found. "America is the wealthiest nation, but its drug prices are significantly higher – so much ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Tamoxifen, Medroxyprogesterone, Arimidex, Tretinoin, Fluorouracil, Lupron Depot, Femara, Lung Cancer, Gleevec, Colorectal Cancer, Isotretinoin, Rituxan, Zoladex

Venclexta Approved for Specific Genetic Blood Cancer

Posted 12 Apr 2016 by Drugs.com

MONDAY, April 11, 2016 – Venclexta (venetoclax) has been approved by the U.S. Food and Drug Administration to treat chronic lymphocytic leukemia (CLL) characterized by a specific chromosomal abnormality called the 17p deletion. People with this abnormality lack a portion of a chromosome that thwarts cancer growth, the agency said in a news release. It occurs in 10 percent to 20 percent of people with CLL. The newly approved drug targets the BCL-2 protein, which promotes cancer growth and often is overabundant in people with CLL, the FDA said. Venclexta's effectiveness was tested in clinical studies involving 106 people with CLL who also had the 17p deletion abnormality. Some 80 percent of trial participants showed a complete or partial remission, the agency said. The drug's most common side effects included low white blood cell count, diarrhea, nausea, anemia, upper respiratory ... Read more

Related support groups: Chronic Lymphocytic Leukemia (CLL), Venclexta, Venetoclax

FDA Approves Venclexta (venetoclax) for Chronic Lymphocytic Leukemia with 17p Deletion

Posted 12 Apr 2016 by Drugs.com

April 11, 2016 – The U.S. Food and Drug Administration today approved Venclexta (venetoclax) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion and who have been treated with at least one prior therapy. Venclexta is the first FDA-approved treatment that targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with CLL. According to the National Cancer Institute, CLL is one of the most common types of leukemia in adults, with approximately 15,000 new cases diagnosed each year. CLL is characterized by the progressive accumulation of abnormal lymphocytes, a type of white blood cell. Patients with CLL who have a 17p deletion lack a portion of the chromosome that acts to suppress cancer growth. This chromosomal abnormality occurs in approximately 10 ... Read more

Related support groups: Leukemia, Chronic Lymphocytic Leukemia (CLL), Venclexta, Venetoclax

Ask a Question

Further Information

Related Condition Support Groups

Chronic Lymphocytic Leukemia (CLL)

Venclexta Patient Information at Drugs.com